NxStage Medical (NSDQ:NXTM) touted FDA clearance for high flow capabilities for the company’s System One home hemodialysis technology, a device the company calls the "only truly portable hemodialysis system cleared for home use."
The Lawrence, Mass.-based medical device maker plans to launch new higher flow System One devices later this year, according to a press release.
"This latest regulatory milestone reflects strong and systematic execution against our product pipeline," CEO Jeffrey Burbank said in prepared remarks. "With this new capability, NxStage therapy may be prescribed less frequently, for example 3 times per week or every other day, at treatment times consistent with those that patients and physicians experience in-center today."
"We’re strong believers in longer and more frequent dialysis for the clinical benefits," he added. "Still, high flow opens the NxStage solution more broadly to the patient segment that wants the benefits of home, but at in-center frequency."
NXTM shares got a boost on Wall Street today, trading 1.5% higher to $11.19 as of about 1:45 p.m.
